
Pericarditis Market Report 2026
Global Outlook – By Type (Acute Pericarditis, Chronic Pericarditis, Recurrent Pericarditis), By Diagnosis And Treatment (Electrocardiogram (ECG), Echocardiogram, Computerized Tomography (Ct), X-Ray, Medication, Surgical Treatment), By Application (Hospitals And Clinics, Medical Institutes, Ambulatory Surgical Centers, Research Organizations) – Market Size, Trends, Strategies, and Forecast to 2035
Pericarditis Market Overview
• Pericarditis market size has reached to $2.49 billion in 2025 • Expected to grow to $3.64 billion in 2030 at a compound annual growth rate (CAGR) of 7.9% • Growth Driver: Rising Cardiovascular Disease Rates Fueling Growth In The Pericarditis Devices Market • Market Trend: Next-Generation Monoclonal Antibodies in Pediatric Care • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Pericarditis Market?
Pericarditis refers to inflammation and irritation of the thin, saclike tissue called pericardium that is surrounding the heart. The common symptom is chest pain, which is caused when sac layers are rubbing against the heart and inflamed. The major types of pericarditis are acute pericarditis, chronic pericarditis, and recurrent pericarditis. Acute pericarditis refers to a painful inflammation that develops suddenly in the pericardium that surrounds your heart. Pericarditis can be diagnosed and treated by electrocardiogram (ECG), echocardiogram, computerized tomography (CT), x-ray, medication, and surgical treatment. Treatment of pericarditis is used in several applications, such as hospitals and clinics, medical institutes, ambulatory surgical centers, and research organizations.
What Is The Pericarditis Market Size and Share 2026?
The pericarditis market size has grown strongly in recent years. It will grow from $2.49 billion in 2025 to $2.69 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to limited awareness of pericarditis, reliance on traditional diagnostics, low adoption of advanced imaging, restricted access to specialized cardiac care, predominance of hospital-based treatment.What Is The Pericarditis Market Growth Forecast?
The pericarditis market size is expected to see strong growth in the next few years. It will grow to $3.64 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to growing prevalence of cardiovascular disorders, increasing adoption of digital diagnostics, expansion of outpatient surgical centers, rising investment in precision medicine, integration of AI in cardiac care. Major trends in the forecast period include personalized pericarditis treatment approaches, minimally invasive surgical techniques, early diagnostic innovations, integration of wearable cardiac monitoring, expansion of outpatient cardiac care services.Global Pericarditis Market Segmentation
1) By Type: Acute Pericarditis, Chronic Pericarditis, Recurrent Pericarditis 2) By Diagnosis And Treatment: Electrocardiogram (ECG), Echocardiogram, Computerized Tomography (Ct), X-Ray, Medication, Surgical Treatment 3) By Application: Hospitals And Clinics, Medical Institutes, Ambulatory Surgical Centers, Research Organizations Subsegments: 1) By Acute Pericarditis: Viral Pericarditis, Bacterial Pericarditis, Idiopathic Pericarditis 2) By Chronic Pericarditis: Constrictive Pericarditis, Non-constrictive Chronic Pericarditis 3) By Recurrent Pericarditis: Post-Acute Pericarditis Recurrences, Secondary Recurrent PericarditisWhat Are The Drivers Of The Pericarditis Market?
The increasing prevalence of cardiovascular diseases is expected to propel the pericarditis market growth going forward. Cardiovascular diseases refer to a term for the conditions affecting the heart or blood vessels. It is usually linked to a buildup of fatty deposits inside the artery and an increased risk of blood clotting. Pericarditis can lead to many cardiovascular diseases or death in extreme cases if it is not treated, so increasing rates of cardiovascular diseases propel the market. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the pericarditis devices market. The increased healthcare spending is expected to boost the growth of the pericarditis market going forward. Healthcare spending refers to the total financial resources allocated for various aspects of healthcare services and activities within a specific region, country, or healthcare system. Increased healthcare spending creates an environment that supports the comprehensive management of pericarditis, from research and diagnosis to treatment and patient education, ultimately benefiting individuals affected by this condition. For instance, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023. Therefore, the increased healthcare spending is driving the growth of the pericarditis industry.Key Players In The Global Pericarditis Market
Major companies operating in the pericarditis market are Pfizer Inc., AstraZeneca plc, Merck & Co. Inc., Novartis International AG, Johnson & Johnson Services Inc., Takeda Pharmaceutical Co. Ltd., Zydus Cadila Healthcare Ltd., Sun Pharmaceutical Ltd., Kiniksa Pharmaceuticals Ltd., Regeneron Pharmaceuticals Inc., Amgen Inc., Merck KGaA, Hikma Pharmaceuticals plc, AbbVie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Bayer AG, Roche Holding AG, Daiichi Sankyo Company Limited, Astellas Pharma Inc.Global Pericarditis Market Trends and Insights
Major companies operating in the pediatric market are developing next-generation monoclonal antibodies to enhance treatment options, improve therapeutic outcomes, and reduce side effects for children with various medical conditions. Next-generation monoclonal antibodies are engineered to provide improved efficacy, specificity, and safety in targeting diseases. For instance, in January 2024, Coherus BioSciences, a US-based biotechnology company, launched LOQTORZITM. LOQTORZI is used in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC). It can also be used as a monotherapy for patients with recurrent, unresectable, or metastatic NPC who have progressed after platinum-containing chemotherapy, regardless of PD-L1 status.Regional Insights
North America was the largest region in the pericarditis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the pericarditis market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.What Defines the Pericarditis Market?
The pericarditis market consists of sales of bacterial pericarditis, viral pericarditis, constrictive pericarditis, and subacute pericarditis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The pericarditis market is segmented into bacterial pericarditis, viral pericarditis, constrictive pericarditis and other pericarditis.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.What Key Data and Analysis Are Included in the Pericarditis Market Report 2026?
The pericarditis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pericarditis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Pericarditis Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $2.69 billion |
| Revenue Forecast In 2035 | $3.64 billion |
| Growth Rate | CAGR of 7.9% from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Type, Diagnosis And Treatment, Application |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | Pfizer Inc., AstraZeneca plc, Merck & Co. Inc., Novartis International AG, Johnson & Johnson Services Inc., Takeda Pharmaceutical Co. Ltd., Zydus Cadila Healthcare Ltd., Sun Pharmaceutical Ltd., Kiniksa Pharmaceuticals Ltd., Regeneron Pharmaceuticals Inc., Amgen Inc., Merck KGaA, Hikma Pharmaceuticals plc, AbbVie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Bayer AG, Roche Holding AG, Daiichi Sankyo Company Limited, Astellas Pharma Inc. |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
